SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, announced its participation in the HC Wainwright 27th Annual Global Investment Conference.
The company's presentation is scheduled for September 5, 2025, at 7:00 am ET. Investors can access the presentation through the Events & Presentations page in the Investor Relations section of SeaStar Medical's website, where it will remain available for 60 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, ICU declined 2.95%, reflecting a moderate negative market reaction. Argus tracked a trough of -12.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $733K from the company's valuation, bringing the market cap to $24M at that time.
Data tracked by StockTitan Argus on the day of publication.
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27th Annual Global Investment Conference.
The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medical website, and will be available for 60 days following the presentation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. It was approved in 2024 by the U.S. Food and Drug Administration (FDA). QUELIMMUNE is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the US annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
IR@SEASTARMED.COM
FAQ
When is SeaStar Medical (ICU) presenting at the HC Wainwright Conference?
How can investors access SeaStar Medical's HC Wainwright Conference presentation?
How long will SeaStar Medical's HC Wainwright presentation be available online?
What is SeaStar Medical's (ICU) business focus?
